Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke - Way to endeavor

被引:33
|
作者
Huang, Poyin [1 ]
Chen, Chun-Hung [1 ]
Yang, Yuan-Han [1 ]
Lin, Ruey-Tay [1 ]
Lin, Feng-Cheng [1 ]
Liu, Ching-Kuan [1 ]
机构
[1] Kaohsiung Med Univ, Chung Ho Mem Hosp 100, Dept Neurol, Kaohsiung 807, Taiwan
关键词
eligibility; stroke; tissue plasminogen activator; stroke code;
D O I
10.1159/000094994
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The eligibility for recombinant tissue plasminogen activator (rtPA) is rare. We analyze the reasons for exclusion from rtPA among patients who were admitted to our hospital within 3 h. Methods: A strict protocol for hyper-acute stroke was set in a university teaching hospital. Consecutive patients activating the protocol from June 2004 to October 2005 were prospectively registered and entered into a computerized database. The patients were excluded from rtPA according to the modified exclusion criteria from the National Institute of Neurological Disorders and Stroke rtPA trial. Results: Of the 182 patients activating the protocol, only 11 (6.04%) received intravenous rtPA and 4 (2.2%) IA thrombolysis. Patients were excluded for multiple reasons, and the main reasons for exclusion were minor or improving stroke (46.15%), hypertension (35.16%), insufficient time to complete studies or onset beyond 3 h after reconfirmation (24.17%) and intracranial hemorrhage (15.93%). Of 167 excluded patients, 72 (43.11%) were excluded by a single criterion, 53 (31.73%) by 2 criteria and 29 (17.36%) by 3 criteria. The mean time from hospital arrival to presentation to a neurologist was 9.24 +/- 15.11 min (n = 164, median = 8.00, mode = 10, range = 0-65). The mean time from hospital arrival to computed tomography (CT) was 21.67 +/- 23.95 min (n = 167, median = 20.00, mode = 10, range = 4-68). Conclusion: An intrahospital stroke code was implemented to minimize intrahospital delay. However, only 11 patients received intravenous rtPA and 4 IA thrombolysis at our hospital from June 2004 to October 2005. The result brings into question the neurologist's conservative interpretation of the criteria and the necessity to clearly define some criteria. Furthermore an intrahospital stroke code should also be implemented for inpatients to maximize the eligibility for rtPA. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:423 / 428
页数:6
相关论文
共 50 条
  • [21] Cost-Effectiveness of Recombinant Tissue Plasminogen Activator in the Management of Acute Ischemic Stroke: A Systematic Review
    Jung, Kee-Taig
    Shin, Dong Wook
    Lee, Kyung-Jin
    Oh, Myungju
    JOURNAL OF CLINICAL NEUROLOGY, 2010, 6 (03): : 117 - 126
  • [22] Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke
    El Amki, Mohamad
    Lerouet, Dominique
    Coqueran, Berard
    Curis, Emmanuel
    Orset, Cyrille
    Vivien, Denis
    Plotkine, Michel
    Marchand-Leroux, Catherine
    Margaill, Isabelle
    EXPERIMENTAL NEUROLOGY, 2012, 238 (02) : 138 - 144
  • [23] Use of recombinant tissue plasminogen activator in cancer patients with acute stroke
    Jerome J. Graber
    Lakshmi Nayak
    Lisa M. DeAngelis
    Journal of Neuro-Oncology, 2012, 107 : 571 - 573
  • [24] Safety and Effectiveness of Intravenous Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Patients on Aspirin and Clopidogrel
    Qureshi, Mushtaq H.
    Khan, Shayaan M.
    Jahangir, Nauman
    Malik, Ahmed A.
    Freese, Melissa
    Thompson, Michelle
    Khan, Asif A.
    Suri, M. Fareed K.
    Qureshi, Adnan I.
    STROKE, 2015, 46
  • [25] Use of recombinant tissue plasminogen activator in cancer patients with acute stroke
    Graber, Jerome J.
    Nayak, Lakshmi
    DeAngelis, Lisa M.
    JOURNAL OF NEURO-ONCOLOGY, 2012, 107 (03) : 571 - 573
  • [26] Tissue plasminogen activator and patients with acute ischemic stroke: The litigation landscape
    Ganti, Latha
    Kwon, Bryan
    George, Andrew
    Stead, Thor
    Plamoottil, Cherian
    Banerjee, Paul
    JOURNAL OF THE AMERICAN COLLEGE OF EMERGENCY PHYSICIANS OPEN, 2022, 3 (01)
  • [27] Intraarterial recombinant tissue plasminogen activator for ischemic stroke: An accelerating dosing regimen
    Qureshi, AI
    Suri, MFK
    Shatla, AA
    Ringer, AJ
    Fessler, RD
    Ali, Z
    Guterman, LR
    Hopkins, LN
    NEUROSURGERY, 2000, 47 (02) : 473 - 476
  • [28] Cost-Utility of Intravenous Recombinant Tissue Plasminogen Activator in the Treatment of Acute Ischemic Stroke: a Systematic Review
    Niknam, Kian
    Dollar, Krista
    Pellegrini, Eric
    Kim, Anthony
    STROKE, 2018, 49
  • [29] Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Patients Receiving Thrombectomy: Standard or Low Dose Therapy?
    Lin, Chun-Hsien
    Liu, Chi-Hung
    Wang, Alvin Yi-Chou
    Wu, Yi-Ming
    Chen, Ching-Chang
    Tsai, Yuan-Hsiung
    Chang, Ting-Yu
    Huang, Kuo-Lun
    Wu, Hsiu-Chuan
    Lee, Tsong-Hai
    Chang, Yeu-Jhy
    Lin, Chuan-Min
    Cheng, Chih-Kuang
    Chang, Chien-Hung
    CURRENT NEUROVASCULAR RESEARCH, 2018, 15 (03) : 204 - 210
  • [30] Low-dose Tissue Plasminogen Activator is as Effective as Standard Tissue Plasminogen Activator Administration for the Treatment of Acute Ischemic Stroke
    Chen, Hui
    Zhu, Guangming
    Liu, Nan
    Zhang, Weiwei
    CURRENT NEUROVASCULAR RESEARCH, 2014, 11 (01) : 62 - 67